drugset / Trial / NCT02862210

Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia

NCT02862210

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Frontotemporal dementia (FTD) is a progressive neurodegenerative illness that affects the frontal and anterior temporal lobes of the brain. Changes in behavior, including agitation, aggression, and repetitive behaviors, are common symptoms in FTD. The investigators currently do not have good medications to treat these symptoms in FTD, and the medications the investigators use often have side effects. In this project, the investigators will test the use of low-dose lithium, compared to a placebo pill, for the treatment of behavioral symptoms in FTD. Lithium greatly reduces the behavioral symptoms of bipolar disorder, and many have found low-dose lithium to be well-tolerated in patients with dementia. Lithium appears to inhibit the creation of a protein involved in many cases of FTD called tau.

Timeline

Start
2017-01-27
Primary completion
2022-11-20
Completion
2022-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Lithium Carbonate Unknown 600 mg